Sensus Healthcare (NASDAQ:SRTS) Price Target Lowered to $10.00 at Maxim Group

Sensus Healthcare (NASDAQ:SRTS) had its target price trimmed by Maxim Group from $14.00 to $10.00 in a research note published on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on SRTS. Lake Street Capital cut their price target on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Sensus Healthcare in a report on Friday, April 4th.

Sensus Healthcare Trading Up 6.1%

NASDAQ:SRTS opened at $4.73 on Monday. Sensus Healthcare has a 12-month low of $4.01 and a 12-month high of $9.33. The stock’s 50 day simple moving average is $4.61 and its 200-day simple moving average is $6.10. The firm has a market cap of $78.02 million, a P/E ratio of 11.83 and a beta of 1.30.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.20). The firm had revenue of $8.34 million during the quarter, compared to analyst estimates of $7.23 million. Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. Research analysts forecast that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC acquired a new stake in shares of Sensus Healthcare in the 1st quarter worth approximately $26,000. JPMorgan Chase & Co. acquired a new position in Sensus Healthcare during the fourth quarter worth $27,000. Barclays PLC purchased a new stake in Sensus Healthcare during the fourth quarter worth $35,000. BNP Paribas Financial Markets purchased a new stake in Sensus Healthcare during the fourth quarter worth $47,000. Finally, Chapin Davis Inc. grew its holdings in Sensus Healthcare by 50.0% in the first quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $71,000 after purchasing an additional 5,000 shares during the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.